Spain · Series A startup

Who invested in Nanoligent

One round we have observed, with the 3 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$14Mraised across 1 round since 2025, from 1 source

Latest round
Series A, $14MOct 2025
Investors
3
See who backed them

The rounds

  1. Oct 2025

Founders and team

From Nanoligent's own website: 4 on the team.

  • Antonio Herce.Director at Life Sciences Inveready.
  • Beatriz Soria.Analyst at Clave Capital
  • Ignacio Prieto.Analyst at Clave Capital
  • Translational Oncology(Josep Carrera’s Senior Researcher)

Everyone who backed them

InvereadyVC firm1round
IAG Capital PartnersPrivate equity1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 2 firms list Nanoligent as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

Clave CapitalVC firmPer its own site
Master CapitalAngel networkPer its own site

Quick answers about Nanoligent

Who invested in Nanoligent?

Nanoligent's investors include Inveready, Italian Angels for Growth and IAG Capital Partners.

How much has Nanoligent raised?

Nanoligent has raised $14M across 1 round since 2025.

When did Nanoligent last raise?

Nanoligent's most recent round was a Series A of $14M in Oct 2025.

What was Nanoligent's biggest round?

Its most recent round, $14M in Oct 2025, is also its largest on record.

Who backed Nanoligent first?

Nanoligent's first round on record, in Oct 2025, was backed by Inveready, Italian Angels for Growth and IAG Capital Partners.

What stage is Nanoligent at?

Nanoligent's latest named round is a Series A, in Oct 2025.

Where is Nanoligent based?

Nanoligent is based in Spain.

Companies like Nanoligent

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.